Future Perspectives of POSEIDON Stratification for Clinical Practice and Research.
ART calculator
Bologna criteria
POSEIDON criteria
blastocyst
controlled ovarian stimulation
low ovarian response
pregnancy
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2019
2019
Historique:
received:
04
04
2019
accepted:
18
06
2019
entrez:
30
7
2019
pubmed:
30
7
2019
medline:
30
7
2019
Statut:
epublish
Résumé
A total of 50% of patients undergoing IVF treatment has previously been estimated to fulfill the POSEIDON classification criteria; importantly, although the reproductive prognosis differs between patients, POSEIDON patients share the same characteristic of a low ovarian response to exogenous gonadotropin stimulation-independent of age. POSEIDON patients require focused attention as regards ovarian stimulation in order to increase the chances of having at least one euploid blastocyst for transfer-the success criterion for stimulation set forth by the POSEIDON Group. The key to success seems to be individualization in all steps of treatment. In this perspective article we discuss the future impact of the POSEIDON stratification for daily clinical practice as well as for research.
Identifiants
pubmed: 31354620
doi: 10.3389/fendo.2019.00439
pmc: PMC6637950
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
439Références
J Clin Endocrinol Metab. 2000 Sep;85(9):3365-9
pubmed: 10999835
Hum Reprod. 2005 Feb;20(2):390-6
pubmed: 15576390
Fertil Steril. 2004 Dec;82(6):1521-6
pubmed: 15589853
Reprod Biol Endocrinol. 2014 Feb 20;12:17
pubmed: 24555766
Swiss Med Wkly. 2015 Feb 06;145:w14087
pubmed: 25668217
Hum Reprod. 2015 Nov;30(11):2563-74
pubmed: 26401054
Fertil Steril. 2016 Jun;105(6):1452-3
pubmed: 26921622
Fertil Steril. 2016 Jun;105(6):1488-1495.e1
pubmed: 27020168
F1000Res. 2016 Dec 23;5:2911
pubmed: 28232864
Reprod Biol Endocrinol. 2018 Mar 9;16(1):20
pubmed: 29523204
Fertil Steril. 2018 Apr;109(4):644-664
pubmed: 29653717
Hum Reprod Update. 2018 Sep 1;24(5):599-614
pubmed: 29924306
Panminerva Med. 2019 Mar;61(1):3-10
pubmed: 29962186
Front Endocrinol (Lausanne). 2018 Jun 14;9:317
pubmed: 29963011
Panminerva Med. 2019 Mar;61(1):24-29
pubmed: 30021418
Front Endocrinol (Lausanne). 2018 Jul 23;9:361
pubmed: 30083131
Front Endocrinol (Lausanne). 2018 Oct 17;9:589
pubmed: 30386293
Reprod Biol Endocrinol. 2019 Feb 6;17(1):18
pubmed: 30728019
Reprod Biomed Online. 2019 May;38(5):677-682
pubmed: 30795977
Front Endocrinol (Lausanne). 2019 Feb 28;10:99
pubmed: 30873117